QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products

Qiagen (QGEN) Tops Q4 EPS by 23c

February 8, 2022 4:08 PM EST

Qiagen (NYSE: QGEN) reported Q4 EPS of $0.75, $0.23 better than the analyst estimate of $0.52. Revenue for the quarter came in at $582 million versus the consensus estimate of $456.63 million.

GUIDANCE:

Qiagen sees FY 2022 EPS of $2.05, versus the consensus of $1.77. Qiagen sees FY 2022... More